Valo Announces Exclusive Partnership with G3 the World's Largest and Detailed Cardio-Metabolic Datasets
BOSTON, Dec. 22, 2020 /PRNewswire/ -- Valo Health, LLC (Valo), has announced an exclusive drug discovery and development partnership with Global Genomics Group, (G3), giving Valo access to the largest and most-detailed cardio-metabolic dataset in the world. Since the inception of the partnership, Valo has identified subpopulations across the cardiometabolic spectrum that have not been resolved before now, and are leading to the discovery of underlying genetics, biomarkers, and new disease-modifying targets. Using its Opal Computational Platform, Valo has been able to identify six validated targets and approximately 20 early potential targets and disease subpopulations.
"This partnership fits perfectly into Valo's strategy to utilize deep clinical human disease data with the powerful platform we have built to redefine diseases and identify sub diseases and patient populations," said Brett Blackman, Valo's Chief Innovation Officer. "At the heart of Valo is our strong belief that human-centric data, coupled with leading-edge computation, will transform and accelerate how drugs are discovered and developed."
Valo is using their machine learning algorithms and G3's high dimensional best-in-class patient data to resolve never before patient-disease subpopulations that guide their discovery of novel targets. This provides confidence in identifying the right patient population to develop a disease-modifying medicine at the start of a discovery program. Valo's Opal Computational Platform takes the novel target and rapidly creates clinical candidates to test in those populations, dramatically cutting time and cost while increasing the probability of a drug's success.
"Working with Valo we are poised to transform and de-risk drug development, based on genetic validation of drug targets and on the use of biomarkers to conduct precision clinical trials in the right patient populations," said Szilard Voros, CEO, and co-founder of Global Genomics Group (G3). "For years, everyone has been talking about genetics -and biomarker-driven clinical trials - with Valo, we are actually now doing it."
G3's proprietary data comes from the Genetic Loci and the Burden of Atherosclerotic Lesions (GLOBAL) clinical study (NCT01738828) and represents one of the largest such disease-centric data sets in the world, designed and executed by G3. The GLOBAL study generated extremely large and complex data sets including whole genome sequencing and phenotypic associations to identify and link biological target (genotype) - phenotype - biomarker(s) as well as 3 billion data points from each of the nearly 8,000 patients with cardiovascular disease and from control subjects. G3 has over 320K blood samples and 8,000 advanced CT imaging datasets for evaluation, all standardized, normalized, and curated.
About G3 Therapeutics
View original content to download multimedia:http://www.prnewswire.com/news-releases/valo-announces-exclusive-partnership-with-g3-the-worlds-largest-and-detailed-cardio-metabolic-datasets-301197305.html
SOURCE Valo Health, LLC